Realcan Pharmaceutical Group Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 6,105.06 million compared to CNY 10,896.72 million a year ago. Net income was CNY 19.22 million compared to CNY 61.08 million a year ago.

Basic earnings per share from continuing operations was CNY 0.0128 compared to CNY 0.0406 a year ago. Diluted earnings per share from continuing operations was CNY 0.0128 compared to CNY 0.0406 a year ago.